CLINICAL TRIALS PROFILE FOR MOEXIPRIL HYDROCHLORIDE

All Clinical Trials for Moexipril Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00588302 ↗	Moexipril for Primary Biliary Cirrhosis	Completed	UCB Pharma	Phase 2	2003-06-01	The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).
NCT00588302 ↗	Moexipril for Primary Biliary Cirrhosis	Completed	Mayo Clinic	Phase 2	2003-06-01	The blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We aimed to determine the safety and efficacy of moexipril, an angiotensin-converting enzyme (ACE) inhibitor, on liver biochemistries, Mayo risk score, and health-related quality of life in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA).
NCT00834067 ↗	Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2003-10-01	The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions.
NCT00835042 ↗	Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2003-10-01	The objective of this study is to compare the relative bioavailability of Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult non-smoking subjects under fasting conditions.
NCT00990301 ↗	A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions	Completed	Paddock Laboratories, Inc.	Phase 1	1969-12-31	The purpose of this study was to evaluate the relative bioavailability of Paddock Laboratories, Inc.'s test formulation of Moexipril/ Hydrochlorothiazide 15mg/25mg tablets with a reference formulation Uniretic®(Moexipril/ Hydrochlorothiazide) 15mg/25mg tablets, under fasting conditions.
NCT00992862 ↗	A Relative Bioavailability Study of Moexipril HCl 15 mg Tablets Under Fasting Conditions	Completed	Paddock Laboratories, Inc.	Phase 1	1969-12-31	The purpose of this study is to compare the relative bioavailability of Moexipril HCl 15mg tablets (by Paddock Laboratories, Inc.) with that of Univasc® 15mg tablets (by Schwarz Pharma) following a single oral dose (1 x 15mg tablet) in healthy, adult subjects under fasting conditions.
NCT01669434 ↗	Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery	Completed	University of Nebraska	Phase 4	2015-06-01	Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience better postoperative control of hypertension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of a non-cardiac, non-vascular surgery will experience less acute renal failure than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively. Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who continue their chronic ACEI therapy up to and including the morning of a non-cardiac, non-vascular surgery will experience more intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.

Clinical Trial Conditions for Moexipril Hydrochloride

Condition Name

Condition Name for Moexipril Hydrochloride
Intervention	Trials
Healthy	4
Hypertension	1
Hypotension on Induction	1
Primary Biliary Cirrhosis	1

Condition MeSH

Condition MeSH for Moexipril Hydrochloride
Intervention	Trials
Fibrosis	1
Hypotension	1
Liver Cirrhosis, Biliary	1
Liver Cirrhosis	1

Clinical Trial Locations for Moexipril Hydrochloride

Trials by Country

Trials by Country for Moexipril Hydrochloride
Location	Trials
United States	8

Trials by US State

Trials by US State for Moexipril Hydrochloride
Location	Trials
Missouri	2
Pennsylvania	2
Texas	2
Minnesota	1
Nebraska	1

Clinical Trial Progress for Moexipril Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Moexipril Hydrochloride
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1
Phase 1	4

Clinical Trial Status

Clinical Trial Status for Moexipril Hydrochloride
Clinical Trial Phase	Trials
Completed	6

Clinical Trial Sponsors for Moexipril Hydrochloride

Sponsor Name

Sponsor Name for Moexipril Hydrochloride
Sponsor	Trials
Teva Pharmaceuticals USA	2
Paddock Laboratories, Inc.	2
UCB Pharma	1

Sponsor Type

Sponsor Type for Moexipril Hydrochloride
Sponsor	Trials
Industry	5
Other	2